Context:
Recently, Scientists from the Institute of Advanced Study in Science and Technology (IASST), Guwahati, and IIT Guwahati have developed an experimental cancer drug called RK-251. It is designed to remain mostly inactive in the body and become active mainly inside cancer cells. The research was published in the Journal of Medicinal Chemistry in 2026.
What is RK-251?
-
-
- RK-251 is a prodrug, meaning it is a less-active form of a medicine that becomes active only when it receives a particular chemical signal.
- The drug uses a difference between cancer and normal cells. Many cancer cells contain higher amounts of Reactive Oxygen Species (ROS), molecules that can damage cells when present in excess.
- RK-251 is a prodrug, meaning it is a less-active form of a medicine that becomes active only when it receives a particular chemical signal.
-
How Does it Work?
The process is simple:
-
-
- When RK-251 enters a cancer cell with high ROS levels, ROS activates the drug and releases NBDHEX.
- NBDHEX blocks an enzyme called GSTP1, which helps some cancer cells survive and resist treatment.
- Thus, RK-251 aims to deliver its cancer-fighting action mainly where it is needed.
- When RK-251 enters a cancer cell with high ROS levels, ROS activates the drug and releases NBDHEX.
-
Theranostic Approach:
RK-251 also contains a fluorescent component called QCy7. When the drug becomes active, it produces a near-infrared light signal.
Therefore, the drug can potentially do two jobs:
-
-
- Treatment: Releases NBDHEX to attack cancer cells.
- Detection: Produces fluorescence to show that the drug has been activated.
- Treatment: Releases NBDHEX to attack cancer cells.
-
Combining treatment and detection is called a theranostic approach.
Target: Triple-Negative Breast Cancer
The drug showed promising activity against triple-negative breast cancer (TNBC) in laboratory studies.
TNBC is difficult to treat because the cancer cells do not have three common targets: oestrogen receptors, progesterone receptors and HER2.
Can it Replace Chemotherapy?
-
-
- It is too early to say that RK-251 can replace chemotherapy. Conventional chemotherapy can damage some healthy cells along with cancer cells, while RK-251 aims to be more selective.
- Before human use, researchers must establish its safety, correct dosage, behaviour in the human body and effectiveness against tumours.
- Even if successful, it may become another treatment option rather than completely replace chemotherapy.
- It is too early to say that RK-251 can replace chemotherapy. Conventional chemotherapy can damage some healthy cells along with cancer cells, while RK-251 aims to be more selective.
-
Significance for India:
RK-251 highlights India's progress in biotechnology, drug discovery, cancer research and precision medicine. It also shows the importance of collaboration between research institutions and IITs.
About Breast Cancer:
-
-
- Breast cancer is the most common cancer among women globally. WHO estimates that about 2.4 million women were diagnosed and 694,000 died from breast cancer in 2024. Early detection and timely treatment are crucial for reducing mortality.
- In India, breast cancer is among the country's most common cancers, alongside cervical and oral cancers, highlighting the importance of screening and early diagnosis.
- Breast cancer is the most common cancer among women globally. WHO estimates that about 2.4 million women were diagnosed and 694,000 died from breast cancer in 2024. Early detection and timely treatment are crucial for reducing mortality.
-
Conclusion:
RK-251 is a promising experimental smart drug that uses high ROS levels inside cancer cells as a trigger. By combining targeted treatment with cancer-cell detection, it represents an interesting development in modern cancer research. However, human clinical trials are still required to establish whether it is safe and effective.
